Trickey Adam, May Margaret T, Schommers Philipp, Tate Jan, Ingle Suzanne M, Guest Jodie L, Gill M John, Zangerle Robert, Saag Mike, Reiss Peter, Monforte Antonella d'Arminio, Johnson Margaret, Lima Viviane D, Sterling Tim R, Cavassini Matthias, Wittkop Linda, Costagliola Dominique, Sterne Jonathan A C
School of Social and Community Medicine, University of Bristol, United Kingdom.
Department I for Internal Medicine, University Hospital of Cologne, Germany.
Clin Infect Dis. 2017 Sep 15;65(6):959-966. doi: 10.1093/cid/cix466.
We investigated whether CD4:CD8 ratio and CD8 count were prognostic for all-cause, AIDS, and non-AIDS mortality in virologically suppressed patients with high CD4 count.
We used data from 13 European and North American cohorts of human immunodeficiency virus-infected, antiretroviral therapy (ART)-naive adults who started ART during 1996-2010, who were followed from the date they had CD4 count ≥350 cells/μL and were virologically suppressed (baseline). We used stratified Cox models to estimate unadjusted and adjusted (for sex, people who inject drugs, ART initiation year, and baseline age, CD4 count, AIDS, duration of ART) all-cause and cause-specific mortality hazard ratios for tertiles of CD4:CD8 ratio (0-0.40, 0.41-0.64 [reference], >0.64) and CD8 count (0-760, 761-1138 [reference], >1138 cells/μL) and examined the shape of associations using cubic splines.
During 276526 person-years, 1834 of 49865 patients died (249 AIDS-related; 1076 non-AIDS-defining; 509 unknown/unclassifiable deaths). There was little evidence that CD4:CD8 ratio was prognostic for all-cause mortality after adjustment for other factors: the adjusted hazard ratio (aHR) for lower vs middle tertile was 1.11 (95% confidence interval [CI], 1.00-1.25). The association of CD8 count with all-cause mortality was U-shaped: aHR for higher vs middle tertile was 1.13 (95% CI, 1.01-1.26). AIDS-related mortality declined with increasing CD4:CD8 ratio and decreasing CD8 count. There was little evidence that CD4:CD8 ratio or CD8 count was prognostic for non-AIDS mortality.
In this large cohort collaboration, the magnitude of adjusted associations of CD4:CD8 ratio or CD8 count with mortality was too small for them to be useful as independent prognostic markers in virally suppressed patients on ART.
我们调查了在病毒学抑制且CD4计数较高的患者中,CD4:CD8比值和CD8计数是否可预测全因死亡率、艾滋病相关死亡率和非艾滋病相关死亡率。
我们使用了来自13个欧洲和北美队列的数据,这些队列研究对象为1996年至2010年期间开始接受抗逆转录病毒治疗(ART)的初治成人人类免疫缺陷病毒感染者,从他们CD4计数≥350个细胞/μL且病毒学抑制(基线)之日起进行随访。我们使用分层Cox模型来估计未经调整和调整后(针对性别、注射毒品者、ART起始年份以及基线年龄、CD4计数、艾滋病、ART持续时间)的全因死亡率和特定病因死亡率风险比,分别针对CD4:CD8比值(0 - 0.40、0.41 - 0.64[参考值]、>0.64)和CD8计数(0 - 760、761 - 1138[参考值]、>1138个细胞/μL)的三分位数,并使用三次样条函数检验关联的形状。
在276526人年的随访期间,49865名患者中有1834人死亡(249例与艾滋病相关;1076例为非艾滋病定义性死亡;509例死因不明/无法分类)。几乎没有证据表明在调整其他因素后,CD4:CD8比值可预测全因死亡率:较低三分位数与中间三分位数相比的调整后风险比(aHR)为1.11(95%置信区间[CI],1.00 - 1.25)。CD8计数与全因死亡率的关联呈U形:较高三分位数与中间三分位数相比的aHR为1.13(95%CI,1.01 - 1.26)。与艾滋病相关的死亡率随着CD4:CD8比值的增加和CD8计数的减少而下降。几乎没有证据表明CD4:CD8比值或CD8计数可预测非艾滋病相关死亡率。
在这项大型队列合作研究中,CD4:CD8比值或CD8计数与死亡率的调整后关联程度过小,以至于它们无法作为接受ART且病毒学抑制患者的独立预后标志物。